ArticleIntensive care medicine experimental2026
Preclinical evidence for supra-clinical acute kidney injury: current biomarkers are not enough.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Preclinical evidence for supra-clinical acute kidney injury: current biomarkers are not enough.Intensive care medicine experimental · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) is a frequent complication in hospitalized patients, affecting up to 50% of those in intensive care units (ICU). It is linked to high morbidity and mortality, with severity closely tied to patient outcomes. While early biomarkers like KIM1 and NGAL can detect subclinical AKI, their practical benefit is limited, as treatment must begin at suspicion rather than biomarker confirmation. Conversely, when injury exceeds serum creatinine's diagnostic capacity, a "blind spot" emerges, highlighting the need for "supra-clinical" AKI biomarkers. The KDIGO staging system, based on urine output and creatinine, lacks granularity: even in stage 3, outcomes range from full recovery to permanent dialysis. Anuric patients, despite complete loss of filtration, also show heterogeneous recovery, suggesting injury severity influences prognosis. This study aims to explore "supra-clinical" AKI and assess whether further injury occurs beyond current clinical markers using a preclinical ischemia-reperfusion model and human single-cell transcriptomic data.
resultsWe performed unilateral renal ischemia of increased duration (5-30 minutes), associated with contralateral nephrectomy, in mice. Plasma urea and creatinine concentration reached a plateau when ischemia duration exceeded 10 minutes. In contrast, we observed a continuous increase in the severity of the renal lesions with the ischemia duration. Similarly, the expression level of Quinolinate phosphoribosyltransferase (QPRT), an enzyme contributing to the biosynthesis of nicotinamide adenine dinucleotide (NAD), was inversely correlated to the ischemia duration. Using single-nucleus RNA sequencing data on human kidney biopsies from ICU patients, we showed a largely reciprocal distribution of QPRT and KIM1 (Kidney Injury Marker 1), expressed specifically in injured proximal tubule cells.
conclusionsOur data demonstrate the existence of a "supra-clinical" stage in AKI, where more ischemia causes more histological and metabolic injury than serum creatinine, serum urea and KIM1 expression can reflect. This highlights a critical diagnostic blind spot: there are currently no available biomarkers to distinguish several stages of AKI when the plasma creatinine concentration does not increase further, or in patients treated with dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.